• Dengue, a significant global health issue, has led to the development of TAK-003 (Qdenga) by Takeda Pharmaceuticals.

• This live attenuated tetravalent vaccine, utilizing a chimeric approach with serotype 2 as the backbone and elements from serotypes 1, 3, and 4, is designed to combat all four dengue virus strains.

• It will be available as either a reconstituted solution or a single-use vial or syringe.

• TAK-003 is administered in two 0.5 ml subcutaneous doses three months apart and is licensed for individuals aged 4 and older.

• Tested in the TIDES clinical trial across Asia and Latin America, the vaccine demonstrated 80.2% efficacy against dengue and 90% against hospitalization during the first 11 months post-vaccination.

• However, its efficacy against DENV-3 and DENV-4 was lower in those not previously exposed to the virus, leading to its recommendation in regions with high dengue transmission.

• TAK-003 is well-tolerated, with adverse effects comparable to placebo, and is contraindicated in pregnant or lactating women, the immunocompromised, and those allergic to its components.

• Endorsed for use in endemic regions by WHO for children aged 6-16, it is also advised for travelers previously infected with dengue and individuals with specific comorbid conditions.

• Despite some efficacy challenges over time, TAK-003 remains a critical tool in reducing the global burden of dengue.

Click here to read more.